Patents by Inventor Ramesh Kaul

Ramesh Kaul has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Non-lysosomal glucosylceramidase inhibitors and uses thereof
    Patent number: 12612380
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Grant
    Filed: May 7, 2020
    Date of Patent: April 28, 2026
    Assignee: ALECTOS THERAPEUTICS 1NC
    Inventors: Ramesh Kaul, Ernest J. Mceachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Non-lysosomal glucosylceramidase inhibitors and uses thereof
    Patent number: 12528773
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Grant
    Filed: May 6, 2021
    Date of Patent: January 20, 2026
    Assignee: ALECTOS THERAPEUTICS INC.
    Inventors: Ramesh Kaul, Ernest J. Mceachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230348387
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: November 2, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20230174486
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 6, 2021
    Publication date: June 8, 2023
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF
    Publication number: 20220213058
    Abstract: The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: May 7, 2020
    Publication date: July 7, 2022
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 10081601
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Grant
    Filed: September 21, 2017
    Date of Patent: September 25, 2018
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Glycosidase inhibitors and uses thereof
    Patent number: 9938299
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: April 10, 2018
    Assignees: ALECTOS THERAPEUTICS, INC., MERCK SHARP & DOHME CORP.
    Inventors: Harold G. Selnick, Kun Liu, Ernest J. McEachern, Ramesh Kaul, Zhongyong Wei, Yaode Wang, Jiang Chang
  • GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF
    Publication number: 20180009761
    Abstract: The invention provides compounds for modulating glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.
    Type: Application
    Filed: September 21, 2017
    Publication date: January 11, 2018
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9815861
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 11, 2015
    Date of Patent: November 14, 2017
    Assignees: Alectos Therapeutics, Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Changwei Mu, Harold G. Selnick, David J. Vocadlo, Yaode Wang, Zhongyong Wei, Yuanxi Zhou, Yongbao Zhu
  • Glucocerebrosidase modulators and uses thereof
    Patent number: 9796680
    Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.
    Type: Grant
    Filed: December 22, 2014
    Date of Patent: October 24, 2017
    Assignee: Alectos Therapeutics Inc.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Jianyu Sun, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9718854
    Abstract: The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Grant
    Filed: March 20, 2012
    Date of Patent: August 1, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang
  • Glycosidase inhibitors and uses thereof
    Patent number: 9695197
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: October 30, 2013
    Date of Patent: July 4, 2017
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Qun Dang, Harold G. Selnick
  • GLUCOCEREBROSIDASE MODULATORS AND USES THEREOF
    Publication number: 20170029379
    Abstract: The invention provides isofogamine analogs of structural formula (I) below that modulate and stabilize glucocerebrosidases and enhance their enzymatic activity in vivo. Such compounds, prodrugs and compositions thereof are useful in treating synucleinopathy, lysosomal storage disease and relevant neurodegenerative disease.
    Type: Application
    Filed: December 22, 2014
    Publication date: February 2, 2017
    Applicant: Alectos Therapeutics Inc.
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Jianyu SUN, David J. VOCADLO, Yuanxi ZHOU, Yongbao ZHU
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20160194337
    Abstract: A locking arrangement secures together first and second panels. The arrangement includes locking tabs (54, 56, 58) projecting from an end edge (64) of the first panel (12) and locking slits (50a, 50b, 50c) in the second panel (28). Each locking slit is provided for receiving a respective one of the locking tabs. The locking tabs and the locking slits are engageable by relative sliding movement with each other. At least one of the locking tabs and locking slits is configured to secure the first and second panels in a first overlapping position while at least another one of the locking tabs and locking slits is configured to secure the first and second panels in a second overlapping position.
    Type: Application
    Filed: December 8, 2013
    Publication date: July 7, 2016
    Inventors: HAROLD G. SELNICK, KUN LIU, ERNEST J. MCEACHERN, RAMESH KAUL, ZHONGYONG WEI, YAODE WANG, JIANG CHANG
  • N-PIPERIDINYL ACETAMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
    Publication number: 20160175315
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Application
    Filed: June 29, 2015
    Publication date: June 23, 2016
    Inventors: Hassan PAJOUHESH, Ramesh KAUL, Yanbing DING, Yongbao ZHU, Lingyun ZHANG, Nagasree CHAKKA, Michael Edward GRIMWOOD, Jason TAN, Yuanxi ZHOU
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20160096858
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: December 11, 2015
    Publication date: April 7, 2016
    Inventors: Ramesh KAUL, Ernest J. MCEACHERN, Changwei MU, Harold G. SELNICK, David J. VOCADLO, Yaode WANG, Zhongyong WEI, Yuanxi ZHOU, Yongbao ZHU
  • Selective glycosidase inhibitors and uses thereof
    Patent number: 9243020
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: January 26, 2016
    Assignees: Alectos Therapeutics Inc., Merck Sharp & Dohme Corp.
    Inventors: Ramesh Kaul, Ernest J. McEachern, Harold G. Selnick, David J. Vocadlo, Yuanxi Zhou, Yongbao Zhu
  • GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20150291620
    Abstract: The invention provides compounds with enhanced permeability for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc.
    Type: Application
    Filed: October 30, 2013
    Publication date: October 15, 2015
    Inventors: Ramesh Kaul, Ernest J. Mceachern, David J. Vocadlo, Yuanxi Zhou, Qun Dang, Harold G. Selnick
  • N-piperidinyl acetamide derivatives as calcium channel blockers
    Patent number: 9096522
    Abstract: Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted T-type calcium channel activity are disclosed. Specifically, a series of compounds containing N-piperidinyl acetamide derivatives as shown in formula (1).
    Type: Grant
    Filed: August 29, 2013
    Date of Patent: August 4, 2015
    Assignee: Zalicus Pharmaceuticals, Ltd.
    Inventors: Hassan Pajouhesh, Ramesh Kaul, Yanbing Ding, Yongbao Zhu, Lingyun Zhang, Nagasree Chakka, Michael Edward Grimwood, Jason Tan, Yuanxi Zhou
  • SELECTIVE GLYCOSIDASE INHIBITORS AND USES THEREOF
    Publication number: 20140088028
    Abstract: The invention provides compounds of formula (I) with substituents as specified in Claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the compounds. The invention also provides methods of treating diseases and disorders related to over-expression of O-GlcNAcase or accumulation of O-GlcNac.
    Type: Application
    Filed: March 20, 2012
    Publication date: March 27, 2014
    Inventors: Ramesh Kaul, Ernest J. McEachern, David J. Vocadlo, Yuanxi Zhou, Kun Liu, Harold G. Selnick, Zhongyong Wei, Changwei Mu, Yaode Wang, Xiaona Wang